First-in-human test targets metastatic clear cell kidney cancer

A PET/CT scan at Peking Union Medical College Hospital in Beijing showed tumors taking up 68 Ga-NYM096, the diagnostic half of a new radiotheranostic pair. In first-in-human testing, the same research team then used 177 Lu-NYM096 to deliver targeted radiation to patients with metastatic clear cell renal cell carcinoma, or ccRCC.

The approach relies on a small molecule aimed at carbonic anhydrase IX, known as CAIX, an enzyme overexpressed in ccRCC. The diagnostic and therapeutic compounds use the same targeting strategy but carry different radioactive isotopes: one helps reveal where the disease is, while the other is used to treat it. That pairing is designed to select patients whose tumors show CAIX expression before radiation is administered.

The researchers first tested the compounds in mice bearing ccRCC tumors. Both versions accumulated strongly in the tumors, and 177 Lu-NYM096 produced a dose-dependent tumor-suppression effect while being well tolerated in the animal models.

The early human study involved patients whose metastatic ccRCC had progressed after standard therapy. They received serial whole-body scans, followed by 177 Lu-NYM096 for those with positive CAIX expression in a standard dose-escalation study. The reported evaluation found no evidence of kidney, liver or pancreatic toxicity, but it did find gastric toxicity. Follow-up imaging showed evidence of tumor response.

So what changes in practice? Not yet a new standard treatment: the evidence is preclinical plus first-in-human, and the reported study is focused on safety, radiation dose and preliminary efficacy. But for selected patients with treatment-resistant metastatic ccRCC, the pair offers a way to see whether tumors carry the target and then send radiation toward those lesions. The stomach signal is a concrete limit, and the researchers say it will guide safer versions of the treatment.